Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 9/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.39 |
| ▸ | MVD | P53602 | 1/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9437039 | 0.94 | LPAR3 (0.45) | LPAR3LPAR2LPAR1SMPD1GGPS1 | |
| SCHEMBL23740318 | 0.83 | LPAR3 (0.40) | LPAR3LPAR2LPAR1SMPD1GGPS1 | |
| SCHEMBL25746259 | 0.83 | CYP3A4 (0.36) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL19940084 | 0.83 | LPAR3 (0.37) | LPAR3LPAR2LPAR1 | |
| SCHEMBL14080914 | 0.83 | ALDH1A1 (0.50) | — | |
| SCHEMBL19917830 | 0.82 | LPAR3 (0.61) | LPAR3LPAR2LPAR1SMPD1 | |
| SCHEMBL9437046 | 0.82 | LPAR3 (0.61) | LPAR3LPAR2LPAR1SMPD1 | |
| SCHEMBL19917793 | 0.82 | LPAR3 (0.61) | LPAR3LPAR2LPAR1SMPD1 | |
| Trolamine SCHEMBL10435731 | 0.81 | LPAR3 (0.36) | LPAR3LPAR2LPAR1 | |
| SCHEMBL10435732 | 0.81 | LPAR3 (0.36) | LPAR3LPAR2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271982-A1 | CODRUG THAT DISINTEGRATES IN INTESTINE, PREPARATION THEREFOR, AND USE THEREOF | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271982-A1 | CODRUG THAT DISINTEGRATES IN INTESTINE, PREPARATION THEREFOR, AND USE THEREOF | VIP, SI, PDCD5 | LPAR3 2759/4885LPAR2 2570/4885LPAR1 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.